TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX) had its price objective cut by equities researchers at Canaccord Genuity Group from $152.00 to $124.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 70.05% from the company’s current price.

A number of other analysts have also recently commented on TMDX. Needham & Company LLC reduced their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Piper Sandler reduced their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Stifel Nicolaus dropped their price objective on TransMedics Group from $130.00 to $85.00 and set a “hold” rating for the company in a research note on Wednesday. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $135.00.

TransMedics Group Stock Down 23.2%

Shares of TMDX stock traded down $22.01 during mid-day trading on Wednesday, hitting $72.92. The company’s stock had a trading volume of 7,727,054 shares, compared to its average volume of 979,563. TransMedics Group has a 52-week low of $70.00 and a 52-week high of $156.00. The business has a 50-day moving average price of $116.57 and a 200 day moving average price of $125.96. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 14.88 and a beta of 2.07.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.48 million. TransMedics Group had a net margin of 31.43% and a return on equity of 30.17%. The firm’s revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 EPS. Research analysts predict that TransMedics Group will post 2.48 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the sale, the insider directly owned 13,091 shares in the company, valued at $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Nicholas Corcoran sold 2,966 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $412,629.92. Following the sale, the insider owned 29,831 shares in the company, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock valued at $2,353,002 in the last 90 days. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of TMDX. Royal Bank of Canada raised its holdings in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares during the period. Goldman Sachs Group Inc. increased its holdings in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. Russell Investments Group Ltd. boosted its position in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after acquiring an additional 938 shares in the last quarter. Finally, M&T Bank Corp bought a new stake in TransMedics Group during the 2nd quarter valued at $209,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Quarterly revenue growth and continued product demand — TMDX posted Q1 revenue up ~21% year‑over‑year driven by strong demand for its Organ Care System (OCS), showing continued top‑line momentum. PR Newswire: Q1 Results
• Positive Sentiment: Some analysts remain bullish despite cuts — Several firms trimmed price targets but retained buy/overweight stances (e.g., TD Cowen, Piper Sandler, Needham), signaling that some investors still see multi‑quarter upside from long‑term adoption. Benzinga: Analyst Notes
• Neutral Sentiment: Guidance updated — Management issued FY‑2026 revenue guidance in a range that brackets Wall Street consensus (roughly $727M–$757M vs. $739M consensus), leaving some ambiguity about margin and EPS sensitivity to execution. Slide Deck / Press Release
• Neutral Sentiment: Earnings call transcript available — Management commentary on adoption, logistics growth and margin drivers is available for investors to review for signs of durable improvement. Seeking Alpha: Call Transcript
• Negative Sentiment: Significant EPS miss and margin pressure — TMDX reported $0.30 EPS vs. ~$0.62 consensus and noted falling margins, which is the primary near‑term catalyst for the share decline. Zacks: Q1 Miss & Margins
• Negative Sentiment: Analyst downgrades and price‑target cuts — Multiple firms cut targets and at least one downgraded TMDX to market‑perform, amplifying selling pressure despite some retained buy ratings. Finviz: Analyst Actions
• Negative Sentiment: Market reaction: heavy volume and reset valuation — The combination of the EPS miss, margin concerns and analyst re‑rating produced elevated trading and a rapid re‑pricing versus recent moving averages. Zacks: Earnings & Revenue Miss

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.